APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anti-Obesity Prescription

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Anti-Obesity Prescription Market Outlook and Growth Opportunities 2026

22 December 2025191 pages

Choose your research edition.

Industry ResearchAnti-Obesity Prescription Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Anti-Obesity Prescription Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal Anti-Obesity Prescription Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anti-Obesity Prescription Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Anti-Obesity Prescription Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Anti-Obesity Prescription market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Anti-Obesity Prescription is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Anti-Obesity Prescription is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Anti-Obesity Prescription is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Anti-Obesity Prescription market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Anti-Obesity Prescription market include Akrimax Pharmaceuticals, Alpex Pharma, Arena Pharmaceuticals, Arrowhead Research, Bridge BioResearch, Compellis Pharmaceuticals, Yungjin Pharm, Zealand Pharma and Zydus Cadila, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Anti-Obesity Prescription market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Anti-Obesity Prescription and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Anti-Obesity Prescription sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Anti-Obesity Prescription market size, projected growth trends, production technologies, key applications, and end-use industries.

Anti-Obesity Prescription Segment by Company

Akrimax Pharmaceuticals

Alpex Pharma

Arena Pharmaceuticals

Arrowhead Research

Bridge BioResearch

Compellis Pharmaceuticals

Yungjin Pharm

Zealand Pharma

Zydus Cadila

Anti-Obesity Prescription Segment by Type

Lorcaserin

Liraglutide

Phentermine and Topiramate

Orlistat

Bupropion and Naltrexone

Anti-Obesity Prescription Segment by Application

E-Commerce

Retail Pharmacies

Hospital Pharmacies

Anti-Obesity Prescription Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Anti-Obesity Prescription status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Anti-Obesity Prescription market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Anti-Obesity Prescription significant trends, drivers, influence factors in global and regions.

6. To analyze Anti-Obesity Prescription competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-Obesity Prescription market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anti-Obesity Prescription and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-Obesity Prescription.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Anti-Obesity Prescription market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Anti-Obesity Prescription industry.

Chapter 3: Detailed analysis of Anti-Obesity Prescription manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Anti-Obesity Prescription in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Anti-Obesity Prescription in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Anti-Obesity Prescription Industry Trends Table 2. Anti-Obesity Prescription Industry Drivers Table 3. Anti-Obesity Prescription Industry Opportunities and Challenges Table 4. Anti-Obesity Prescription Industry Restraints Table 5. Global Anti-Obesity Prescription Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Anti-Obesity Prescription Revenue Share by Company (2021-2026) Table 7. Global Anti-Obesity Prescription Sales Volume by Company (k units) & (2021-2026) Table 8. Global Anti-Obesity Prescription Sales Volume Share by Company (2021-2026) Table 9. Global Anti-Obesity Prescription Average Price (US$/unit) of Company (2021-2026) Table 10. Global Anti-Obesity Prescription Company Ranking, (2024-2026) & (USD Million) Table 11. Global Anti-Obesity Prescription Key Company Manufacturing Base & Headquarters Table 12. Global Anti-Obesity Prescription Company, Product Type & Application Table 13. Global Anti-Obesity Prescription Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Anti-Obesity Prescription by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Lorcaserin Table 18. Significant Companies of Liraglutide Table 19. Significant Companies of Phentermine and Topiramate Table 20. Significant Companies of Orlistat Table 21. Significant Companies of Bupropion and Naltrexone Table 22. Global Anti-Obesity Prescription Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 23. Global Anti-Obesity Prescription Sales Volume by Type (2021-2026) & (k units) Table 24. Global Anti-Obesity Prescription Sales Volume by Type (2027-2032) & (k units) Table 25. Global Anti-Obesity Prescription Sales Volume Share by Type (2021-2026) Table 26. Global Anti-Obesity Prescription Sales Volume Share by Type (2027-2032) Table 27. Global Anti-Obesity Prescription Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Anti-Obesity Prescription Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Anti-Obesity Prescription Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Anti-Obesity Prescription Sales Value Share by Type (2021-2026) Table 31. Global Anti-Obesity Prescription Sales Value Share by Type (2027-2032) Table 32. Significant Companies of E-Commerce Table 33. Significant Companies of Retail Pharmacies Table 34. Significant Companies of Hospital Pharmacies Table 35. Global Anti-Obesity Prescription Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 36. Global Anti-Obesity Prescription Sales Volume by Application (2021-2026) & (k units) Table 37. Global Anti-Obesity Prescription Sales Volume by Application (2027-2032) & (k units) Table 38. Global Anti-Obesity Prescription Sales Volume Share by Application (2021-2026) Table 39. Global Anti-Obesity Prescription Sales Volume Share by Application (2027-2032) Table 40. Global Anti-Obesity Prescription Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Anti-Obesity Prescription Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Anti-Obesity Prescription Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Anti-Obesity Prescription Sales Value Share by Application (2021-2026) Table 44. Global Anti-Obesity Prescription Sales Value Share by Application (2027-2032) Table 45. Global Anti-Obesity Prescription Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 46. Global Anti-Obesity Prescription Sales by Region (2021-2026) & (k units) Table 47. Global Anti-Obesity Prescription Sales Market Share by Region (2021-2026) Table 48. Global Anti-Obesity Prescription Sales by Region (2027-2032) & (k units) Table 49. Global Anti-Obesity Prescription Sales Market Share by Region (2027-2032) Table 50. Global Anti-Obesity Prescription Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Anti-Obesity Prescription Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Anti-Obesity Prescription Sales Value Share by Region (2021-2026) Table 53. Global Anti-Obesity Prescription Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Anti-Obesity Prescription Sales Value Share by Region (2027-2032) Table 55. Global Anti-Obesity Prescription Market Average Price (US$/unit) by Region (2021-2026) Table 56. Global Anti-Obesity Prescription Market Average Price (US$/unit) by Region (2027-2032) Table 57. Global Anti-Obesity Prescription Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 58. Global Anti-Obesity Prescription Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Anti-Obesity Prescription Sales by Country (2021-2026) & (k units) Table 60. Global Anti-Obesity Prescription Sales Market Share by Country (2021-2026) Table 61. Global Anti-Obesity Prescription Sales by Country (2027-2032) & (k units) Table 62. Global Anti-Obesity Prescription Sales Market Share by Country (2027-2032) Table 63. Global Anti-Obesity Prescription Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Anti-Obesity Prescription Sales Value Market Share by Country (2021-2026) Table 65. Global Anti-Obesity Prescription Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Anti-Obesity Prescription Sales Value Market Share by Country (2027-2032) Table 67. Akrimax Pharmaceuticals Company Information Table 68. Akrimax Pharmaceuticals Business Overview Table 69. Akrimax Pharmaceuticals Anti-Obesity Prescription Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 70. Akrimax Pharmaceuticals Anti-Obesity Prescription Product Portfolio Table 71. Akrimax Pharmaceuticals Recent Development Table 72. Alpex Pharma Company Information Table 73. Alpex Pharma Business Overview Table 74. Alpex Pharma Anti-Obesity Prescription Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 75. Alpex Pharma Anti-Obesity Prescription Product Portfolio Table 76. Alpex Pharma Recent Development Table 77. Arena Pharmaceuticals Company Information Table 78. Arena Pharmaceuticals Business Overview Table 79. Arena Pharmaceuticals Anti-Obesity Prescription Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 80. Arena Pharmaceuticals Anti-Obesity Prescription Product Portfolio Table 81. Arena Pharmaceuticals Recent Development Table 82. Arrowhead Research Company Information Table 83. Arrowhead Research Business Overview Table 84. Arrowhead Research Anti-Obesity Prescription Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 85. Arrowhead Research Anti-Obesity Prescription Product Portfolio Table 86. Arrowhead Research Recent Development Table 87. Bridge BioResearch Company Information Table 88. Bridge BioResearch Business Overview Table 89. Bridge BioResearch Anti-Obesity Prescription Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 90. Bridge BioResearch Anti-Obesity Prescription Product Portfolio Table 91. Bridge BioResearch Recent Development Table 92. Compellis Pharmaceuticals Company Information Table 93. Compellis Pharmaceuticals Business Overview Table 94. Compellis Pharmaceuticals Anti-Obesity Prescription Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 95. Compellis Pharmaceuticals Anti-Obesity Prescription Product Portfolio Table 96. Compellis Pharmaceuticals Recent Development Table 97. Yungjin Pharm Company Information Table 98. Yungjin Pharm Business Overview Table 99. Yungjin Pharm Anti-Obesity Prescription Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 100. Yungjin Pharm Anti-Obesity Prescription Product Portfolio Table 101. Yungjin Pharm Recent Development Table 102. Zealand Pharma Company Information Table 103. Zealand Pharma Business Overview Table 104. Zealand Pharma Anti-Obesity Prescription Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 105. Zealand Pharma Anti-Obesity Prescription Product Portfolio Table 106. Zealand Pharma Recent Development Table 107. Zydus Cadila Company Information Table 108. Zydus Cadila Business Overview Table 109. Zydus Cadila Anti-Obesity Prescription Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 110. Zydus Cadila Anti-Obesity Prescription Product Portfolio Table 111. Zydus Cadila Recent Development Table 112. Key Raw Materials Table 113. Raw Materials Key Suppliers Table 114. Anti-Obesity Prescription Distributors List Table 115. Anti-Obesity Prescription Customers List Table 116. Research Programs/Design for This Report Table 117. Authors List of This Report Table 118. Secondary Sources Table 119. Primary Sources List of Figures Figure 1. Anti-Obesity Prescription Product Image Figure 2. Global Anti-Obesity Prescription Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anti-Obesity Prescription Sales Value (2021-2032) & (US$ Million) Figure 4. Global Anti-Obesity Prescription Sales (2021-2032) & (k units) Figure 5. Global Anti-Obesity Prescription Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Anti-Obesity Prescription Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Lorcaserin Image Figure 10. Liraglutide Image Figure 11. Phentermine and Topiramate Image Figure 12. Orlistat Image Figure 13. Bupropion and Naltrexone Image Figure 14. Global Anti-Obesity Prescription Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global Anti-Obesity Prescription Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Anti-Obesity Prescription Sales Volume Share by Type (2021-2032) Figure 17. Global Anti-Obesity Prescription Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Anti-Obesity Prescription Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Anti-Obesity Prescription Sales Value Share by Type (2021-2032) Figure 20. E-Commerce Image Figure 21. Retail Pharmacies Image Figure 22. Hospital Pharmacies Image Figure 23. Global Anti-Obesity Prescription Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 24. Global Anti-Obesity Prescription Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Anti-Obesity Prescription Sales Volume Share by Application (2021-2032) Figure 26. Global Anti-Obesity Prescription Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Anti-Obesity Prescription Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Anti-Obesity Prescription Sales Value Share by Application (2021-2032) Figure 29. Global Anti-Obesity Prescription Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 30. Global Anti-Obesity Prescription Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Anti-Obesity Prescription Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Anti-Obesity Prescription Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Anti-Obesity Prescription Sales Value (2021-2032) & (US$ Million) Figure 34. North America Anti-Obesity Prescription Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Anti-Obesity Prescription Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Anti-Obesity Prescription Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Anti-Obesity Prescription Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Anti-Obesity Prescription Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Anti-Obesity Prescription Sales Value (2021-2032) & (US$ Million) Figure 40. South America Anti-Obesity Prescription Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Anti-Obesity Prescription Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Anti-Obesity Prescription Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Anti-Obesity Prescription Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Anti-Obesity Prescription Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Anti-Obesity Prescription Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Anti-Obesity Prescription Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Anti-Obesity Prescription Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Anti-Obesity Prescription Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Anti-Obesity Prescription Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Anti-Obesity Prescription Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Anti-Obesity Prescription Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Anti-Obesity Prescription Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Anti-Obesity Prescription Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Anti-Obesity Prescription Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Anti-Obesity Prescription Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Anti-Obesity Prescription Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Anti-Obesity Prescription Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Anti-Obesity Prescription Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Anti-Obesity Prescription Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Anti-Obesity Prescription Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Anti-Obesity Prescription Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Anti-Obesity Prescription Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Anti-Obesity Prescription Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Anti-Obesity Prescription Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Anti-Obesity Prescription Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Anti-Obesity Prescription Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Anti-Obesity Prescription Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Anti-Obesity Prescription Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Anti-Obesity Prescription Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Anti-Obesity Prescription Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Anti-Obesity Prescription Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Anti-Obesity Prescription Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Lorcaserin
  • Liraglutide
  • Phentermine and Topiramate
  • Orlistat
  • Bupropion and Naltrexone
Applications
  • E-Commerce
  • Retail Pharmacies
  • Hospital Pharmacies
Companies covered
  • Akrimax Pharmaceuticals
  • Alpex Pharma
  • Arena Pharmaceuticals
  • Arrowhead Research
  • Bridge BioResearch
  • Compellis Pharmaceuticals
  • Yungjin Pharm
  • Zealand Pharma
  • Zydus Cadila

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Anti-Obesity Prescription Sales Value (2021-2032)
  4. 1.2.2 Global Anti-Obesity Prescription Sales Volume (2021-2032)
  5. 1.2.3 Global Anti-Obesity Prescription Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Anti-Obesity Prescription Market Dynamics
  1. 2.1 Anti-Obesity Prescription Industry Trends
  2. 2.2 Anti-Obesity Prescription Industry Drivers
  3. 2.3 Anti-Obesity Prescription Industry Opportunities and Challenges
  4. 2.4 Anti-Obesity Prescription Industry Restraints
3 Anti-Obesity Prescription Market by Company
  1. 3.1 Global Anti-Obesity Prescription Company Revenue Ranking in 2025
  2. 3.2 Global Anti-Obesity Prescription Revenue by Company (2021-2026)
  3. 3.3 Global Anti-Obesity Prescription Sales Volume by Company (2021-2026)
  4. 3.4 Global Anti-Obesity Prescription Average Price by Company (2021-2026)
  5. 3.5 Global Anti-Obesity Prescription Company Ranking (2024-2026)
  6. 3.6 Global Anti-Obesity Prescription Company Manufacturing Base and Headquarters
  7. 3.7 Global Anti-Obesity Prescription Company Product Type and Application
  8. 3.8 Global Anti-Obesity Prescription Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Anti-Obesity Prescription Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Anti-Obesity Prescription Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Anti-Obesity Prescription Market by Type
  1. 4.1 Anti-Obesity Prescription Type Introduction
  2. 4.1.1 Lorcaserin
  3. 4.1.2 Liraglutide
  4. 4.1.3 Phentermine and Topiramate
  5. 4.1.4 Orlistat
  6. 4.1.5 Bupropion and Naltrexone
  7. 4.2 Global Anti-Obesity Prescription Sales Volume by Type
  8. 4.2.1 Global Anti-Obesity Prescription Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Anti-Obesity Prescription Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Anti-Obesity Prescription Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Anti-Obesity Prescription Sales Value by Type
  12. 4.3.1 Global Anti-Obesity Prescription Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Anti-Obesity Prescription Sales Value by Type (2021-2032)
  14. 4.3.3 Global Anti-Obesity Prescription Sales Value Share by Type (2021-2032)
5 Anti-Obesity Prescription Market by Application
  1. 5.1 Anti-Obesity Prescription Application Introduction
  2. 5.1.1 E-Commerce
  3. 5.1.2 Retail Pharmacies
  4. 5.1.3 Hospital Pharmacies
  5. 5.2 Global Anti-Obesity Prescription Sales Volume by Application
  6. 5.2.1 Global Anti-Obesity Prescription Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Anti-Obesity Prescription Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Anti-Obesity Prescription Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Anti-Obesity Prescription Sales Value by Application
  10. 5.3.1 Global Anti-Obesity Prescription Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Anti-Obesity Prescription Sales Value by Application (2021-2032)
  12. 5.3.3 Global Anti-Obesity Prescription Sales Value Share by Application (2021-2032)
6 Anti-Obesity Prescription Regional Sales and Value Analysis
  1. 6.1 Global Anti-Obesity Prescription Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Anti-Obesity Prescription Sales by Region (2021-2032)
  3. 6.2.1 Global Anti-Obesity Prescription Sales by Region: 2021-2026
  4. 6.2.2 Global Anti-Obesity Prescription Sales by Region (2027-2032)
  5. 6.3 Global Anti-Obesity Prescription Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Anti-Obesity Prescription Sales Value by Region (2021-2032)
  7. 6.4.1 Global Anti-Obesity Prescription Sales Value by Region: 2021-2026
  8. 6.4.2 Global Anti-Obesity Prescription Sales Value by Region (2027-2032)
  9. 6.5 Global Anti-Obesity Prescription Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Anti-Obesity Prescription Sales Value (2021-2032)
  12. 6.6.2 North America Anti-Obesity Prescription Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Anti-Obesity Prescription Sales Value (2021-2032)
  15. 6.7.2 Europe Anti-Obesity Prescription Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Anti-Obesity Prescription Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Anti-Obesity Prescription Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Anti-Obesity Prescription Sales Value (2021-2032)
  21. 6.9.2 South America Anti-Obesity Prescription Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Anti-Obesity Prescription Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Anti-Obesity Prescription Sales Value Share by Country, 2025 VS 2032
7 Anti-Obesity Prescription Country-level Sales and Value Analysis
  1. 7.1 Global Anti-Obesity Prescription Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Anti-Obesity Prescription Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Anti-Obesity Prescription Sales by Country (2021-2032)
  4. 7.3.1 Global Anti-Obesity Prescription Sales by Country (2021-2026)
  5. 7.3.2 Global Anti-Obesity Prescription Sales by Country (2027-2032)
  6. 7.4 Global Anti-Obesity Prescription Sales Value by Country (2021-2032)
  7. 7.4.1 Global Anti-Obesity Prescription Sales Value by Country (2021-2026)
  8. 7.4.2 Global Anti-Obesity Prescription Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Anti-Obesity Prescription Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Anti-Obesity Prescription Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Anti-Obesity Prescription Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Anti-Obesity Prescription Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Anti-Obesity Prescription Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Anti-Obesity Prescription Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Anti-Obesity Prescription Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Anti-Obesity Prescription Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Anti-Obesity Prescription Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Anti-Obesity Prescription Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Anti-Obesity Prescription Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Anti-Obesity Prescription Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Anti-Obesity Prescription Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Anti-Obesity Prescription Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Anti-Obesity Prescription Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Anti-Obesity Prescription Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Anti-Obesity Prescription Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Anti-Obesity Prescription Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Anti-Obesity Prescription Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Anti-Obesity Prescription Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Anti-Obesity Prescription Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Anti-Obesity Prescription Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Anti-Obesity Prescription Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Anti-Obesity Prescription Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Anti-Obesity Prescription Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Anti-Obesity Prescription Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Anti-Obesity Prescription Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Anti-Obesity Prescription Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Anti-Obesity Prescription Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Anti-Obesity Prescription Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Akrimax Pharmaceuticals
  2. 8.1.1 Akrimax Pharmaceuticals Company Information
  3. 8.1.2 Akrimax Pharmaceuticals Business Overview
  4. 8.1.3 Akrimax Pharmaceuticals Anti-Obesity Prescription Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Akrimax Pharmaceuticals Anti-Obesity Prescription Product Portfolio
  6. 8.1.5 Akrimax Pharmaceuticals Recent Developments
  7. 8.2 Alpex Pharma
  8. 8.2.1 Alpex Pharma Company Information
  9. 8.2.2 Alpex Pharma Business Overview
  10. 8.2.3 Alpex Pharma Anti-Obesity Prescription Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Alpex Pharma Anti-Obesity Prescription Product Portfolio
  12. 8.2.5 Alpex Pharma Recent Developments
  13. 8.3 Arena Pharmaceuticals
  14. 8.3.1 Arena Pharmaceuticals Company Information
  15. 8.3.2 Arena Pharmaceuticals Business Overview
  16. 8.3.3 Arena Pharmaceuticals Anti-Obesity Prescription Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Arena Pharmaceuticals Anti-Obesity Prescription Product Portfolio
  18. 8.3.5 Arena Pharmaceuticals Recent Developments
  19. 8.4 Arrowhead Research
  20. 8.4.1 Arrowhead Research Company Information
  21. 8.4.2 Arrowhead Research Business Overview
  22. 8.4.3 Arrowhead Research Anti-Obesity Prescription Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Arrowhead Research Anti-Obesity Prescription Product Portfolio
  24. 8.4.5 Arrowhead Research Recent Developments
  25. 8.5 Bridge BioResearch
  26. 8.5.1 Bridge BioResearch Company Information
  27. 8.5.2 Bridge BioResearch Business Overview
  28. 8.5.3 Bridge BioResearch Anti-Obesity Prescription Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Bridge BioResearch Anti-Obesity Prescription Product Portfolio
  30. 8.5.5 Bridge BioResearch Recent Developments
  31. 8.6 Compellis Pharmaceuticals
  32. 8.6.1 Compellis Pharmaceuticals Company Information
  33. 8.6.2 Compellis Pharmaceuticals Business Overview
  34. 8.6.3 Compellis Pharmaceuticals Anti-Obesity Prescription Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Compellis Pharmaceuticals Anti-Obesity Prescription Product Portfolio
  36. 8.6.5 Compellis Pharmaceuticals Recent Developments
  37. 8.7 Yungjin Pharm
  38. 8.7.1 Yungjin Pharm Company Information
  39. 8.7.2 Yungjin Pharm Business Overview
  40. 8.7.3 Yungjin Pharm Anti-Obesity Prescription Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Yungjin Pharm Anti-Obesity Prescription Product Portfolio
  42. 8.7.5 Yungjin Pharm Recent Developments
  43. 8.8 Zealand Pharma
  44. 8.8.1 Zealand Pharma Company Information
  45. 8.8.2 Zealand Pharma Business Overview
  46. 8.8.3 Zealand Pharma Anti-Obesity Prescription Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Zealand Pharma Anti-Obesity Prescription Product Portfolio
  48. 8.8.5 Zealand Pharma Recent Developments
  49. 8.9 Zydus Cadila
  50. 8.9.1 Zydus Cadila Company Information
  51. 8.9.2 Zydus Cadila Business Overview
  52. 8.9.3 Zydus Cadila Anti-Obesity Prescription Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Zydus Cadila Anti-Obesity Prescription Product Portfolio
  54. 8.9.5 Zydus Cadila Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Anti-Obesity Prescription Value Chain Analysis
  2. 9.1.1 Anti-Obesity Prescription Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Anti-Obesity Prescription Sales Mode & Process
  6. 9.2 Anti-Obesity Prescription Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Anti-Obesity Prescription Distributors
  9. 9.2.3 Anti-Obesity Prescription Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst